Preview

Артериальная гипертензия

Расширенный поиск

Локальныежировые депо как фактор риска сердечно-сосудистых заболеваний

https://doi.org/10.18705/1607-419X-2010--5-

Полный текст:

Аннотация

Ожирение ассоциируется с риском развития сердечно-сосудистой патологии. Одним из механизмов, ведущих к сердечно-сосудистым осложнениям является гормональная активность локальных жировых депо. Белая жировая ткань, расположенная в эпикардиальной, висцеральной, паранефральной и периваскулярной областях, оказывает не только локальное механическое воздействие на рядом расположенные органы, но и системное действие через биологически активные вещества. Проатерогенные и провоспалительные хемокины и цитокины вызывают хроническое воспаление сосудистой стенки, пролиферацию и миграцию гладкомышечных клеток, трансформацию моноцитов в макрофаги, что ведет к дисфункции эндотелия, формированию атеросклеротической бляшки и прогрессированию атеросклероза.

Об авторах

Г. А. Чумакова
Алтайский государственный медицинский университет
Россия


Н. Г. Веселовская
Научно-исследовательский институт Комплексных проблем сердечно-сосудистых заболеваний Сибирского отделения РАМН
Россия


А. А. Козаренко
Научно-исследовательский институт Комплексных проблем сердечно-сосудистых заболеваний Сибирского отделения РАМН
Россия


Л. С. Барбараш
Алтайский краевой кардиологический диспансер
Россия


Список литературы

1. Adams K.F., Schatzkin A., Harris T.B. et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old // N. Engl. J. Med. - 2006. - Vol. 355, № 8. - P. 763-778.

2.

3. The challenge of obesity in the WHO European Region // World Health Organization, Copenhagen, Bucharest 12. - 2005.

4.

5. Narayan K.M., Boyle J.P., Geiss L.S. et al. Impact of recent increase in incidence on future diabetes burden: U.S. 2005-2050 // Diabetes Care. - 2006. - Vol. 29, № 9. - P. 2114-2116.

6.

7. Kopelman P.G. Obesity as a medical problem // Nature. - 2000. - Vol. 404, № 6778. - P. 635-643.

8.

9. Bray G.A. Medical consequences of obesity // J. Clin. Endocrinol. Metab. - 2004. - Vol. 89, № 6. - P. 2583-2589.

10.

11. Sharma A.M. Obesity and cardiovascular risk // Growth Horm. IGF Res. - 2003. - Vol. 13 (Suppl A) - P. 10-17.

12.

13. Arcaro G., Zamboni M., Rossi L. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity // Int. J. Obes. Relat. Metab. Disord. - 1999. - Vol. 23, № 9. - P. 936-942.

14.

15. Nieto F.J., Young T.B., Lind B.K. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study // J. Am. Med. Assoc. - 2000. - Vol. 283, № 14. - P. 1829-1836.

16.

17. Jacobson B.C., Somers S.C., Fuchs C.S. Body-mass index and symptoms of gastroesophageal reflux in women //N. Engl. J. Med. - 2006. - Vol. 354, № 22. - P. 2340-2348.

18.

19. Soderberg S., Ahren B., Jansson J.H. et al. Leptin is associated with increased risk of myocardial infarction // J. Intern. Med. - 1999. - Vol. 246, № 4. - P. 409-418.

20.

21. Schnabel R., Messow C.M., Lubos E., et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study // Eur. Heart J. - 2008. - Vol. 29, № 5. - P. 649-657.

22.

23. Rothenbacher D., Brenner H., März W. et al. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers // Eur. Heart J. - 2005. - Vol. 26, № 16. - P. 1640-1646.

24.

25. Koenig W., Khuseyinova N., Baumert J. et al. Serum Concentrations of Adiponectin and Risk of Type 2 Diabetes Mellitus and Coronary Heart Disease in Apparently Healthy Middle-Aged Men // J. Am. Coll. Cardiol. - 2006. - Vol. 48, № 7. - P. 1369-1377.

26.

27. Wallace A.M., McMahon A.D., Packard C.J. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS) // Circulation. - 2001. - Vol. 104, № 25. - P. 3052-3056.

28.

29. Juge-Aubry C.E., Henrichot E., Meier C.A. Adipose tissue: a regulator of inflammation // Best Pract. Res. Clin. Endocrinol. Metab. - 2005. - Vol. 19, № 4. - P. 547-566.

30.

31. Brook R.D. Obesity, weight loss, and vascular function // Endocrine. - 2006. - Vol. 29, № 1. - P. 21-25.

32.

33. Montani J.P., Carroll J.F., Dwyer T.M. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases // Int. J. Obes. Relat. Metab. Disord. - 2004. - Vol. 28 (Suppl. 4). - P. 58-65.

34.

35. Douketis J.D., Sharma A.M. Obesity and cardiovascular disease: pathogenic mechanisms and potential benefits of weight reduction // Semin. Vasc. Med. - 2005. - Vol. 5, № 1. - P. 25-33.

36.

37. Despres J.P. Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease // J. Endocrinol. Invest. - 2006. - Vol. 29, № 3. - P. 77-82.

38.

39. Grundy S.M., Brewer H.B. Jr., Cleeman J.I. et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition // Circulation. - 2004. - Vol. 109, № 3. - P. 433-438.

40.

41. Iacobellis G., Ribaudo M.C., Assael F. et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk // J. Clin. Endocrinol. Metab. - 2003. - Vol. 88, № 11. - P. 5163-5168.

42.

43. Denton R.M., Randle P.J. Concentrations of glycerides and phospholipids in rat heart and gastrocnemius muscles. Effects of alloxan-diabetes and perfusion // Biochem. J. - 1967. - Vol. 104, № 2. - P. 416-422.

44.

45. Pan D.A., Lillioja S., Kriketos A.D. et al. Skeletal muscle triglyceride levels are inversely related to insulin action // Diabetes. - 1997. - Vol. 46, № 6. - P. 983-988.

46.

47. Goodpaster B.H., Theriault R., Watkins S.C. et al. Intramuscular lipid content is increased in obesity and decreased by weight loss // Metabolism. - 2000. - Vol. 49, № 4. - P. 467-472.

48.

49. Dwyer T.M., Mizelle H.L., Cockrell K. Renal sinus lipomatosis and body composition in hypertensive, obese rabbits // Int. J. Obes. Relat. Metab. Disord. - 1995. - Vol. 19, № 12. - P. 869-874.

50.

51. Hall J.E. Mechanisms of abnormal renal sodium handling in obesity hypertension // Am. J. Hypertens. - 1997. - Vol. 10, № 5. - P. 49-55.

52.

53. Baker A.R., Silva N.F., Quinn D.W. et al. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease // Cardiovasc. Diabetol. - 2006. - Vol. 5, № 1. - P. 1-6.

54.

55. Iacobellis G., Assael F., Ribaudo M.C., Zappaterreno A. et al. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction // Obes. Res. - 2003. - Vol. 11, № 2. - P. 304-310.

56.

57. Natale F., Tedesco M., Mocerino R. Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives // Eur. J. Echocardiography. - 2009. - Vol.10, № 4. - P. 549-555.

58.

59. Iacobellis G., Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects // J. Clin. Endocrinol. Metab. - 2005. - Vol. 90, № 11. - P. 6300-6302.

60.

61. Iacobellis G., Gao Y.J., Sharma A.M. Do cardiac and perivascular adipose tissue play a role in atherosclerosis? // Curr. Diab. Rep. - 2008. - Vol. 8, № 1. - P. 20-24.

62.

63. Mazurek T., Zhang L., Zalewski A. et al. Human epicardial adipose tissue is a source of inflammatory mediators // Circulation. - 2003. - Vol. 108, № 20. - P. 2460-2466.

64.

65. Kremen J., Dolinkova M., Krajickova J. et al. Increased subcutaneous and epicardial adipose tissue production of proinflammatory cytokines in cardiac surgery patients: possible role in postoperative insulin resistance // J. Clin. Endocrinol. Metab. - 2006. - Vol. 91, № 11. - P. 4620-4627.

66.

67. Hug C., Lodish H.F. The role of the adipocyte hormone adiponectin in cardiovascular disease // Curr. Opin. Pharmacol. - 2005. - Vol. 5, № 2. -P. 129-134.

68.

69. Silaghi A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Silaghi%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>., Piercecchi-Marti M.D <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Piercecchi-Marti%20MD%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>., Grino M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Grino%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>. Epicardial adipose tissue extent: relationship with age, body fat distribution, and coronaropathy // Obesity <javascript:AL_get(this,%20'jour',%20'Obesity%20(Silver%20Spring).');>. - 2008. - Vol. 16, № 11. - P. 2424-2430.

70.

71. Clément K., Basdevant A., Dutour A. Weight of Pericardial Fat on Coronaropathy // Arterioscler. Thromb. Vasc. Biol. - 2009. - Vol. 29, № 5. - P. 615-618.

72.

73. Ding J., Hsu F., Harris T. The association of pericardial fat with incident coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA) // Am. J. Clin. Nutr. - 2009. - Vol. 90, № 3. - P. 499-504.

74.

75. Lohn M., Dubrovska G., Lauterbach B. Periadventitial fat releases a vascular relaxing factor // FASEB J. - 2002. - Vol. 16, № 9. - P. 1057-1063.

76.

77. Verlohren S., Dubrovska G., Tsang S.Y. et al. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries // Hypertension. - 2004. - Vol. 44, № 3. - P. 271-276.

78.

79. Henrichot E., Juge-Aubry C.E., Pernin A. et al. Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis? // Arterioscler. Thromb. Vasc. Biol. - 2005. - Vol. 25, № 12. - P. 2594-2599.

80.

81. Wildman R.P., Farhat G.N., Patel A.S. et al. Weight change is associated with change in arterial stiffness among healthy young adults // Hypertension. - 2005. - Vol. 45, № 2. - P. 187-192.

82.

83. Gao Y.J., Takemori K., Su L.Y. et al. Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion // Cardiovasc. Res. - 2006. - Vol. 71, № 2. - P. 363-373.

84.

85. Schaffler A., Muller-Ladner U., Scholmerich J. et al. Role of adipose tissue as an inflammatory organ in human diseases // Endocr. Rev. - 2006. - Vol. 27, № 5. - P. 449-467.

86.

87. Herrmann J., Lerman L.O., Mukhopadhyay D. et al. Angiogenesis in atherogenesis // Arterioscler. Thromb. Vasc. Biol. - 2006. - Vol. 26, № 9. - P. 1948-1957.

88.

89. Gerszten R.E., Mach F., Sauty A. et al. Chemokines, leukocytes, and atherosclerosis // J. Lab. Clin. Med. - 2000. - Vol. 136, № 2. - P. 87-92.

90.

91. Yudkin J.S., Eringa E., Stehouwer C.D. «Vasocrine» signaling from perivascular fat: a mechanism linking insulin resistance to vascular disease // Lancet. - 2005. -Vol. 365, №9 473. - P. 1817-1820.

92.

93. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance // Science. - 1993. - Vol. 259, № 5091. - P. 87-91.

94.

95. Scherrer U., Sartori C. Defective nitric oxide synthesis: a link between metabolic insulin resistance, sympathetic over activity and cardiovascular morbidity // Eur. J. Endocrinol. - 2000. - Vol. 142, № 4. - P. 315-323.

96.

97. Hausman D.B., DiGirolamo M., Bartness T.J. et al. The biology of white adipocyte proliferation // Obes. Rev. - 2001. -Vol. 2, № 4. - P. 239-254.

98.

99. Trayhurn P., Beattie J.H. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ // Proc. Nutr. Soc. - 2001. - Vol. 60, № 3. - P. 329-339.

100.

101. Suzawa M., Takada I., Yanagisawa J. et al. Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade // Nat. Cell. Biol. - 2003. - Vol. 5, № 3. - P. 224-230.

102.

103. Ronti T., Lupattelli G., Mannarino E. The endocrine function of adipose tissue: an update // Clin. Endocrinol. (Oxf). - 2006. - Vol. 64, № 4. - P. 355-365.

104.

105. Wallenius V., Wallenius K., Ahren B. et al. Interleukin-6-deficient mice develop mature-onset obesity // Nat. Med. - 2002. - Vol. 8, № 1. - P. 75-79.

106.

107. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation // N. Engl. J. Med. - 1998. - Vol. 338, № 7. - P. 436-445.

108.

109. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy // Curr. Pharm. Des. -2005. - Vol.11, № 18. - P. 2279-2299.

110.

111. Boisvert W.A. Modulation of atherogenesis by chemokines // Trends Cardiovasc. Med. - 2004. - Vol. 14, № 4. - P. 161-165.

112.

113. van Royen N., Hoefer I., Buschmann I. et al. Effects of local MCP-1 protein therapy on the development of the collateral circulation and atherosclerosis in Watanabe hyperlipidemic rabbits // Cardiovasc. Res. - 2003. - Vol. 57, № 1. - P. 178-185.

114.

115. Boring L., Gosling J., Cleary M. et al. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis // Nature. - 1998. - Vol. 394, № 6696. - P. 894-897.

116.

117. Gerhardt C.C., Romero I.A., Cancello R. et al. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes // Mol. Cell. Endocrinol. - 2001. - Vol. 175, № 1. - P. 81-92.

118.

119. Huo Y., Weber C., Forlow S.B. et al. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium // J. Clin. Inves. - 2001. - Vol. 108, № 9. - P. 1307-1314.

120.

121. Boisvert W.A., Santiago R., Curtiss L.K. at al. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice // J. Clin. Invest. - 1998. - Vol. 101, № 2. - P. 353-363.

122.

123. Straczkowski M., Dzienis-Straczkowska S., Stepien A. et al. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system // J. Clin. Endocrinol. Metab. - 2002. -Vol. 87, № 10. - P. 4602-4606.

124.

125. Luster A.D., Oppenheim J.J., Feldmann M. Cytokine reference. - London: New York, 2000. - P. 1103-1109.

126.

127. Boger C.A., Fischereder M., Deinzer M. et al. RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients // Atherosclerosis. - 2005. - Vol. 183, № 1. - P. 121-129.

128.

129. Veillard N.R., Kwak B., Pelli G. et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice // Circ. Res. - 2004. - Vol. 94, № 2. - P. 253-261.

130.

131. Miczke A., Bryl W., Szulinska M. et al. The role of adiponectin in pathogenesis of insulin resistance and metabolic syndrome // Pol. Merkur. Lekarski. - 2005. - Vol. 19, № 113. - P. 723-726.

132.

133. Kadowaki T., Yamauchi T., Kubota N. et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome // J. Clin. Invest. - 2006. - Vol. 116, № 7. - P. 1784-1792.

134.

135. Yamauchi T., Kamon J., Waki H. et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis // J. Biol. Chem. - 2003. - Vol. 278, № 4. - P. 2461-2468.

136.

137. Chandran M., Phillips S.A., Ciaraldi T. et al. Adiponectin: more than just another fat cell hormone? // Diabetes Care. - 2003. - Vol. 26, № 8. - P. 2442-2450.

138.

139. Kumada M., Kihara S., Ouchi N. et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages // Circulation. - 2004. - Vol. 109, № 17. - P. 2046-2049.

140.

141. Lau D.C., Dhillon B., Yan H. et al. Adipokines: molecular links between obesity and atheroslcerosis // Am. J. Physiol. Heart Circ. Physiol. - 2005. - Vol. 288, № 5. - P. 2031-2041.

142.

143. Kumada M., Kihara S., Sumitsuji S. et al. Coronary artery disease Association of hypoadiponectinemia with coronary artery disease in men // Arterioscler. Thromb. Vasc. Biol. - 2003. - Vol. 23, № 1. - P. 85-89.

144.

145. Pischon T., Girman C.J., Hotamisligil G.S. et al. Plasma adiponectin levels and risk of myocardial infarction in men // J. Am. Med. Assoc. - 2004. - Vol. 291, № 14. - P. 1730-1737.

146.

147. Maahs D.M., Ogden L.G., Kinney G.L. et al. Low plasma adiponectin levels predict progression of coronary artery calcification // Circulation. - 2005. - Vol. 111, № 6. - P. 747-753.

148.

149. Azuma K., Katsukawa F., Oguchi S. et al. Correlation between serum resistin level and adiposity in obese individuals // Obes. Res. - 2003. - Vol. 11, № 8. - P. 997-1001.

150.

151. Skilton M.R., Nakhla S., Sieveking D.P. et al. Pathophysiological levels of the obesity related peptides resistin and ghrelin increase adhesion molecule expression on human vascular endothelial cells // Clin. Exp. Pharmacol. Physiol. - 2005. - Vol. 32, № 10. - P. 839-844.

152.

153. Hug C., Lodish H.F. Visfatin: a new adipokine // Science. - 2005. - Vol. 307, № 5708. - P. 366-367.

154.

155. Fukuhara A., Matsuda M., Nishizawa M. et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin // Science. - 2005. - Vol. 307, № 5708. - P. 426-430.

156.

157. Cho Y.M., Youn B.S., Lee H. et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes // Diabetes Care. - 2006. - Vol. 29, № 11. - P. 2457-2461.

158.

159. Graham T.E., Yang Q., Bluher M. et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects // N. Engl. J. Med. - 2006. -Vol. 354, № 24. - P. 2552-2563.

160.

161. Juge-Aubry C.E., Meier C.A. Immunomodulatory actions of leptin // Mol. Cell. Endocrinol. - 2002. - Vol. 194, № 1. - P. 1-7.

162.

163. Chen K., Li F., Li J. Induction of leptin resistance through direct interaction of C-reactive protein with leptin // Nat. Med. - 2006. - Vol. 12, № 4. - P. 425-432.

164.

165. Correia ML, Haynes WG. Leptin, obesity and cardiovascular disease // Curr. Opin. Nephrol. Hypertens. - 2004. - Vol. 13, № 2. -P. 215-223.

166.

167. Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension // J. Hypertens. - 2006. - Vol. 24, № 5. - P. 789-801.

168.

169. Piatti P., Di Mario C., Monti L.D. et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting // Circulation. - 2003. - Vol. 108, № 17. - P. 2074-2081.

170.

171. Wallerstedt S.M., Eriksson A.L., Niklason A. et al. Serum leptin and myocardial infarction in hypertension // Blood Press. - 2004. - Vol.13, № 4. - P. 243-246.

172.

173. Koh K.K., Quon M.J., Lee S.J. et al. Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in non-diabetic patients with hypertension // Diabetes Care. - 2007. - Vol. 30, № 6. - P. 1605-1607.

174.

175. Chiba T., Shinozaki S., Nakazawa T. et al. Leptin deficiency suppresses progression of atherosclerosis in apoE-deficient mice // Atherosclerosis - 2008. -Vol. 196, № 1. - P. 68-75.

176.

177. Corsonello A., Perticone F., Malara A. Leptin-dependent platelet aggregation in healthy, overweight and obese subjects // Int. J. Obes. Relat. Metab. Disord. - 2003. - Vol. 27, № 5. - P. 566-573.

178.

179. Zaman A.K., Fujii S., Sawa H. et al. Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice // Circulation. - 2001. - Vol. 103, № 25. - P. 3123-3128.

180.

181. Thogersen A.M., Jansson J.H., Boman K. et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor // Circulation. - 1998. - Vol. 98, № 21. - P. 2241-2247.


Для цитирования:


Чумакова Г.А., Веселовская Н.Г., Козаренко А.А., Барбараш Л.С. Локальныежировые депо как фактор риска сердечно-сосудистых заболеваний. Артериальная гипертензия. 2010;16(5):441-448. https://doi.org/10.18705/1607-419X-2010--5-

For citation:


Chumakova G.A., Veselovskaya N.G., Kоzarenko A.A., Barbarash L.S. Local fat depots asa cardiovascular risk factor. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2010;16(5):441-448. (In Russ.) https://doi.org/10.18705/1607-419X-2010--5-

Просмотров: 71


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)